Description:
The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma.
The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma.
Active, not recruiting
Phase 2
Drug | Synonyms | Arms |
---|---|---|
Axicabtagene Ciloleucel | Yescarta® | Axicabtagene Ciloleucel |
Fludarabine | Axicabtagene Ciloleucel | |
Cyclophosphamide | Axicabtagene Ciloleucel |
Name | Type | Description | Interventions |
---|---|---|---|
Axicabtagene Ciloleucel | Experimental | Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, axicabtagene ciloleucel |
|
Key Inclusion Criteria: - Histologically confirmed large B-cell lymphoma - High-grade large B-cell lymphoma - Individuals must have a positive interim positron emission tomography (PET) per Cheson, 2014 (Deauville PET score of 4 or 5) after 2 cycles (PET2+) of chemoimmunotherapy - No evidence, suspicion and/or history of CNS involvement of lymphoma - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Absolute neutrophil count ≥ 1000/μL - Platelet count ≥ 75,000/μL - Absolute lymphocyte count ≥ 100/μL - Adequate renal, hepatic, pulmonary, and cardiac function defined as: - Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min - Serum alanine aminotransferase (ALT/AST) ≤ 2.5 upper limit of normal (ULN) - Total bilirubin ≤1.5 mg/dL, except in individuals with Gilbert's syndrome - Cardiac ejection fraction ≥ 50% , no evidence of pericardial effusion as determined by an ECHO, and no clinically significant ECG findings - No clinically significant pleural effusion - Baseline oxygen saturation > 92% on room air Key Exclusion Criteria: - History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (eg cervix, bladder, breast) unless disease free for at least 3 years - History of Richter's transformation of chronic lymphocytic leukemia or primary mediastinal B-cell lymphoma - History of autologous or allogeneic stem cell transplant - Prior CD19-targeted therapy - Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy - Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management - History of HIV infection or acute or chronic active hepatitis B or C infection - Presence of any indwelling line or drain dedicated central venous access catheters, such as a Port-a-Cath or Hickman catheter, are permitted - Individuals with detectable cerebrospinal fluid malignant cells, brain metastases, or active CNS lymphoma - History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement - History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment - History of autoimmune disease resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years - History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Measure: | Complete Response (CR) Rate |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: | Complete Response rate is defined as the incidence of a CR per the Lugano Classification (Cheson et al, 2014), as determined by study investigators. |
Measure: | Objective Response Rate (ORR) |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: | ORR is defined as the incidence of either a CR or a partial response (PR) per the Lugano Classification as determined by study investigators. |
Measure: | Duration of Response (DOR) |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: | DOR is defined only for participants who experience an objective response after axicabtagene ciloleucel infusion and is the time from the first objective response to disease progression or death from any cause. |
Measure: | Event-Free Survival (EFS) |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | EFS is defined as the time from the axicabtagene ciloleucel infusion date to the earliest date of disease progression, commencement of subsequent new anti-lymphoma therapy including stem cell transplant (SCT), or death from any cause. |
Measure: | Progression-Free Survival (PFS) |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: | PFS is defined as the time from the axicabtagene ciloleucel infusion date to the date of disease progression or death from any cause. |
Measure: | Overall Survival (OS) |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | OS is defined as the time from axicabtagene ciloleucel infusion to the date of death from any cause. |
Measure: | Percentage of participants experiencing adverse events and Clinical Significant Changes in Safety Lab Values |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: |
Measure: | Relapse with Central Nervous Disease (CNS) Disease |
Time Frame: | Up to 5 years |
Safety Issue: | |
Description: | Relapse with CNS disease is defined as the time from the axicabtagene ciloleucel infusion date to the earliest date of CNS involvement with lymphoma as determined by typical symptoms, CSF evaluation, and/or diagnostic imaging. |
Measure: | Levels of anti-CD19 CAR T cells in blood |
Time Frame: | Up to 1 year |
Safety Issue: | |
Description: |
Measure: | Levels of cytokines in serum |
Time Frame: | Up to 1 year |
Safety Issue: | |
Description: |
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | Kite, A Gilead Company |
August 18, 2021